Heart failure marker

1 . A method of treating or preventing heart failure in a subject identified as having an increased urinary angiotensinogen amount value, the method comprising:

administering a heart failure drug to the subject identified as having an increased urinary angiotensinogen amount value for treating or preventing heart failure,

wherein the urinary angiotensinogen amount value is a value obtained by measuring an angiotensinogen amount and a creatinine amount in a urine sample collected from the subject at a defined time and dividing urinary angiotensinogen mass by urinary creatinine mass, and the value is converted into “urinary angiotensinogen mass (μg)/urinary creatinine mass (g)”, and

wherein the subject is identified as having an increased urinary angiotensinogen amount value when the measured urinary angiotensinogen amount value is 1.2 times or more than the value measured in a urine sample collected from the subject prior to the defined time.

2 . The method according to claim 1 , wherein

the subject is further a person having risk of heart failure, and the subject is further a person in remission of heart failure, a person who is obese or likely to be obese, a person who has hypertension or is likely to have hypertension, an elderly person, a patient with chronic obstructive pulmonary disease (COPD), a smoker, a diabetic patient or a preliminary diabetic, or

the subject is further a patient with heart failure, and the subject is further a patient with acute heart failure or a patient with exacerbation of chronic heart failure.

3 . The method according to claim 1 , wherein

the subject is further a person having risk of heart failure, and the subject is further a person in remission of heart failure, and

the urine sample collected from the subject prior to the defined time is urine collected at a time of remission of heart failure.

4 . The method according to claim 1 , wherein the subject is further a person having risk of heart failure, and the subject is further a person in remission of heart failure and the person satisfies at least one of requirements i), (ii) and (iii) below at a time of onset of the heart failure:

(i) the subject is 75 years old or older;

(ii) the subject has a history of hypertension;

(iii) the subject has a cardiac function classification severity of New York Heart Association (NYHA) of III or higher.

5 . The method according to claim 1 , wherein

the angiotensinogen amount value of the urine sample collected from the subject prior to the defined time is 250 or less.

6 . The method according to claim 1 , wherein

the subject is further a person who has been hospitalized for acute heart failure, or hospitalized for exacerbation of chronic heart failure,

the subject has been further hospitalized, and

the urine sample collected from the subject at the defined time is urine collected when the subject is further hospitalized.

7 . The method according to claim 1 , wherein

the urinary angiotensinogen amount value is measured by using a kit comprising a reagent for measuring an angiotensinogen amount and a reagent for measuring a creatinine amount.

8 . The method according to claim 7 ,

wherein the reagent for measuring the angiotensinogen amount comprises an anti-angiotensinogen antibody, and

the reagent for measuring the creatinine amount comprises picric acid.

9 . The method according to claim 1 , wherein the angiotensinogen amount value measured in in the urine sample collected from the subject at the defined time is 3.0 times or more the angiotensinogen amount value of the urine sample collected from the subject prior to the defined time.